Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and ...

Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief ...

Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb.

Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...

Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- ...

Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...

H.C. Wainwright downgraded Inhibikase Therapeutics (IKT) to Neutral from Buy without a price target after risvodetinib development was paused ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and Inhibikase Therapeutics, Inc. (IKT) 10-day simple moving average is 2.65. Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and ...